US2007048272A1PendingUtilityA1
Methods of treating cancer using IL-21
Est. expiryJun 7, 2022(expired)· nominal 20-yr term from priority
A61P 37/02A61P 35/04A61P 9/00A61P 37/04A61P 33/02A61P 31/04A61P 31/12A61P 31/16A61P 31/10A61P 35/00A61P 25/00A61P 31/18A61P 31/06A61P 31/20A61P 31/22A61P 35/02A61P 31/14A61P 31/00A61P 11/00A61P 19/02A61P 1/04A61P 1/00A61P 1/16C07K 16/2878C07K 2317/73A61K 38/2026A61K 38/2086A61K 45/06A61K 38/20A61K 38/193C07K 14/54A61K 38/2013Y02A50/30
65
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer therapeutics.
Claims
exact text as granted — not AI-modified1 . A method of expanding anticancer effector cells isolated from a subject for cell adoptive therapy comprising treating isolated cells with an IL-21 polypeptide comprising residues 32 (Gln) to 162 (Ser) of SEQ ID NO:2 to expand the effector cells.
2 . The method of claim 1 , wherein a second cytokine selected from the group consisting of IL-2, Interferon-α, IL-15 and IL-12 is administered to the subject.
3 . The method of claim 1 , wherein the isolated anticancer effector cells are further isolated NK or tumor-specific T cells.Join the waitlist — get patent alerts
Track US2007048272A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.